CHILD ASSENT AND PARENT PERMISSION

This guidance document is intended for investigators who plan to conduct research involving children as subjects. (Also see CPHS Guidelines on Children in Research.) Should you need additional assistance, please contact OPHS at 510-642-7461 or ophs@berkeley.edu.

Table of Contents
A. Introduction
B. Definitions
C. Child Assent
   1. Process Overview
   2. Additional Information
   3. Waiver of Child Assent
D. Parent Permission
   1. General Information
   2. When Parents Disagree
   3. Considerations for Waiver of Parent Permission
E. Documentation of Assent and Permission
   1. General Guidelines by Age Group
   2. Waiver of Documented (Signed) Permission
F. Posting Clinical Trial Consent Forms

A. Introduction

Special ethical and regulatory considerations apply when research involves children as subjects. Children are inherently more vulnerable than adults, requiring a higher level of protection, and are also legally incapable of giving valid informed consent. Thus, the CPHS must assure that adequate provisions are made regarding assent of the child and permission of the parent(s) or guardian(s).

In reviewing such studies, the CPHS will apply the requirements found in federal regulations 45 CFR 46, Subpart D, "Additional Protections for Children Involved as Subjects in Research" (and 21 CFR 50: Subpart D, the corresponding regulations of the FDA), as well as pertinent state and local regulations. Relevant Policies & Procedures of the CPHS can be found on our website under SC-503: Children as a Vulnerable Population and IC-703: Assent and Parent/Guardian Permission.

Issues related to child assent and parent permission are discussed below. For complete topic information, be sure to see companion CPHS guidance on Children in Research.

B. Definitions

1. *Children* are "persons who have not attained the legal age for consent to treatments or procedures involved in the research, under the applicable law of the jurisdiction in which the research will be conducted." (See CPHS Guidelines on Children in Research, Section D, pt. 1, for further discussion on this topic, including definitions of "children" vs. "minors.")

   [Note: In this document, unless otherwise specified, the terms "child(ren)" and "minor(s)" both refer to the definition above.]
2. **Assent** means "a child’s affirmative agreement to participate in research. Mere failure to object should not, absent affirmative agreement, be construed as assent."

3. **Permission** means "the agreement of parent(s) or guardian to the participation of their child or ward in research." (See CPHS guidance on *Children in Research*, Section D, pt. 2 for further discussion on "Wards").

   [Note: In this document, the term "child" is used in place of "child/ward."]

4. **Parent** means "a child’s biological or adoptive parent."

5. **Guardian** means "an individual who is authorized under applicable State or local law to consent on behalf of a child to general medical care."

   [Note: For the remainder of this document, the term "parent(s)" is used in place of "parent(s)/guardian(s)".]

C. Child Assent

1. **Process Overview**

   Federal regulations do not provide many specifics about child assent. They do charge that "adequate provisions [be] made for soliciting the assent of the children, when in the judgment of the IRB the children are capable of providing assent, ...[taking] into account the ages, maturity, and psychological state of the children involved" [45 CFR 46.408].

   Based on this broad outline, National Commission and Committee on Bioethics recommendations, and many expert opinions, the CPHS subscribes to the following standards.

   The process of asking a child to participate in research should be carefully planned and implemented, using age-appropriate language and methods, for any child who is considered capable of understanding and providing assent. This process should include a clear explanation (verbally, and in written form when applicable) that conveys:

   - what the study is about;
   - why the child is eligible/being invited to participate in the study;
   - procedures the child will be expected to take part in;
   - potential risks and/or discomforts to the child;
   - potential benefits to the child or society;
   - that the child is completely free to choose whether or not to participate, and may withdraw at any time without negative consequences;
   - an invitation to ask questions at any time; and
   - names and contact information (phone numbers, email addresses) of whom to contact with questions.

   [Note: See CPHS instructions and template assent forms for assistance. Assent language *must* be tailored to the reading and comprehension level(s) of the subject populations to be enrolled and will vary widely from study to study. When verbal assent only is proposed, an assent script (containing some/all of the elements listed above) may be advised.

   Multiple methods of explaining the study should be used as suitable, e.g., videotapes, online presentations, written materials, diagrams, etc. Younger children are likely to understand verbal explanations better if they are accompanied by concrete examples that the child can relate to past experience. Each child, if capable, should have the opportunity to sign an assent form and take a copy home to review later.

2. **Additional Information**

   The federal regulations do not recommend that assent be sought starting at a specific age (although California law requires assent for experimental medical procedures "if the subject is seven years of age
or older” [CA Health & Safety Code §111530]). The CPHS agrees that, in most cases, seven years of age is a reasonable minimum for a child with normal cognitive development to be capable of participating in a meaningful written assent process, and that many adolescent minors (13 to 17 year olds) will be able to participate in a written assent process that is similar to that of adult consent. (See further discussion below.)

The Committee also agrees that dissent of a child (i.e., their actual objection to research) should be considered binding, especially in non-therapeutic research. (There are rare exceptions, e.g., where a study may offer direct medical benefit to a younger child. See additional information below, under 3-Waiver of Child Assent, Waiver Criteria under 45 CFR 46.408.)

In general:

- If the child is considered capable of being involved in the informational process (regardless of age), at least a simple verbal explanation of what will happen to him/her and the opportunity for questions and discussion should be given. Even if the requirement for assent is waived (see Waiver of Child Assent below), it is always preferable to involve the child in the process as much as possible.

- An appropriate assent form should be used whenever feasible (see CPHS template assent forms). Assent forms should be written at a level of education and maturity appropriate to that of the youngest prospective subject in the age range, and the information delivered using suitable methods. (When verbal assent only is proposed, CPHS still requires an assent script.)

- At a minimum, there must be documentation on the parent permission form and/or in the study records that the child was informed about the study. (See Section E: Documentation of Assent and Permission).

3. Waiver of Child Assent

The CPHS is responsible for deciding whether child assent is required in a proposed research activity. The Committee will require child assent unless it determines that the research satisfies one of these conditions: Waiver Criteria under 45 CFR 46.408:

- The capability of some or all of the children is so limited that they cannot reasonably be consulted; OR
- The research holds out a prospect of direct benefit that is important to the health or well-being of the children and is available only in the context of the research.

Even where the CPHS determines that the children are capable of assenting, it may still waive the assent requirements under circumstances in which consent may be waived for adults:

According to HHS federal regulations (45 CFR 46.116), the CPHS may waive the requirement to obtain informed consent, or it may approve a consent procedure that alters some of the elements of informed consent.

However, the CPHS must first be satisfied that:

1) The research
   (a) presents no risks of harm, considering probability and magnitude, greater than those ordinarily encountered in daily life or during the performance of routine examinations or tests; and
   (b) the research could not practicably be carried out without the waiver or alteration; and
   (c) if the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format; and
(d) the waiver or alteration will not adversely affect the rights and welfare of the subjects; and
(e) whenever appropriate, the subjects or legally authorized representatives will be provided with additional pertinent information after participation.

OR

2) The research or demonstration project is to be conducted by or subject to the approval of state or local government officials and is designed to study, evaluate, or otherwise examine: (a) public benefit or service programs; (b) procedures for obtaining benefits or services under those programs; (c) possible changes in or alternatives to those programs or procedures; or (d) possible changes in methods or levels of payment for benefits or services under those programs; and the research could not practicably be carried out without the waiver or alteration.

Note: Consent waiver is not allowed for FDA-regulated research. In addition, if an individual was asked to provide broad consent for the storage, maintenance, and secondary research use of identifiable private information or identifiable biospecimens, and refused to consent, consent may not be waived for the storage, maintenance, or secondary research use of the identifiable private information or identifiable biospecimens.

3) Informed Consent Exception:

Information or biospecimens for the purpose of screening, recruiting, or determining the eligibility of prospective subjects may be obtained without the informed consent of the prospective subjects or the subject’s legally authorized representative, if either of the following conditions are met:

(a) The investigator will obtain information through oral or written communication with the prospective subject or legally authorized representative; or

(b) The investigator will obtain identifiable private information or identifiable biospecimens by accessing records or stored identifiable biospecimens.

Note: Investigators requesting a waiver of child assent should provide rationale/justification based on one of the criteria described above, in the Child Assent and Parent Permission section of the CPHS application.

D. Parent Permission

1. General: As with child assent, federal regulations do not provide many specifics about parent permission. They do indicate whether permission from one or both parents is required for each category of permissible research (see CPHS Guidelines on Children in Research), and also speak to circumstances in which parent permission may be waived (see Waiver of Parental Permission below).

In most cases, the CPHS expects that the parent(s) will play a vital part in the consent process for research involving their child. The investigator should make every effort to assure that both the parents and child understand the research, and their respective rights, as thoroughly as possible. This includes conveying to parents that they should respect their child's autonomy in this regard (e.g., not exert overt or implied pressure for the child to participate, not indicate anger or disappointment if the child wishes to decline or withdraw from the study). Usually, the parent(s) must be provided with a permission form that meets all requirements for adult consent, but is written to refer to the subject as "your child" instead of "you."

2. When Parents Disagree: If there are two parents available to give permission and the researcher becomes aware that they disagree about allowing their child to participate in the study, the child may not be enrolled unless that disagreement can be resolved. (This applies to all permissible categories; i.e., even if only one parent’s signature is required, when both parents are involved in the decision, they must agree in order for the child to participate).

3. Considerations for Waiver of Parent Permission
The CPHS may waive the requirements for obtaining parent or guardian permission for research involving children if EITHER of the sets of conditions outlined below is met.

- Under 45 CFR 46.116 *(See above under Waiver of Child Assent).*

- Under 45 CFR 46.408: The CPHS may waive the requirement for permission if it finds that "a research protocol is designed to study conditions in children or a subject population for which parent or guardian permission is not a reasonable requirement to protect the subjects (for example, neglected or abused children)."

Research on neglected or abused children is one example for possible waiver; the CPHS interprets this regulation as also applying to people under 18 years of age who are in circumstances where they are clearly outside of parental influence or control (though not legally able to consent for themselves). The Committee will evaluate each waiver request carefully to determine if "parent or guardian permission is not a reasonable requirement to protect the subjects” in that case.

To grant any waiver under 46.408, the Committee must also find that: "(i) an appropriate mechanism for protecting the children who will participate as subjects in the research is substituted; and… (ii) the waiver is not inconsistent with Federal, State, or local law. The choice of an appropriate mechanism [will] depend upon the nature and purpose of the activities described in the protocol, the risk and anticipated benefit to the research subjects, and their age, maturity, status, and condition."

**Waiver of Parent Permission – Additional considerations in school settings:**

- If investigators request waiver of parental permission, waiver must be approved by CPHS at non-exempt level of review.

- The application must state that investigator(s) will work with the school(s) to ensure Family Educational Rights and Privacy Act (FERPA) compliance.

- The application must also state that data collected will not relate to the specified topics listed in the Protection of Pupil Rights Amendment (PPRA), which require written parent permission.

(See CPHS guidance on Children in Research, section D6-e, for more detail on FERPA and PPRA.)

**Note:** Investigators requesting a waiver of parent permission should provide rationale/justification based on one of the conditions described above, in the Child Assent and Parent Permission section of the CPHS application. In cases where parent permission is waived, the IRB will usually require that the investigator provide parents or legally authorized representatives with a written statement regarding the research. The CPHS will expect such an unsigned "information sheet" to be used in place of a consent or permission form.

**Regarding FDA regulations:** No informed consent requirements can be waived for studies regulated by the FDA, except under the FDA emergency treatment or emergency use exception.

E. Documentation of Assent and Permission

The regulations indicate that parent permission must be documented as required for adult consent (per §46.117). Regarding child assent, the regulations state: "When the IRB determines that assent is required, it shall also determine whether and how assent must be documented." (§46.408 (e))

1. The CPHS recommends the following general guidelines for permission and assent by age group of the child subjects, and documentation thereof. **Note:** The CPHS template assent and permission forms can be adapted for use in most studies, using these categories as a basis.

   a. **Children up to 7 years old:** Children in this age range may not be able to participate in a written assent process, or if very young or otherwise incapable, in any meaningful assent process. In such cases, only a
permission form for the parents will be required. This form should be adapted from the CPHS template parent permission forms.

*Note:* In many cases, the investigator may deem a child younger than 7 years old capable of being involved in the assent process. If so, the investigator should make sure that the child is given a simple explanation of what will happen to him/her, and that there is documentation on an assent form/script, the parent permission form, or in the study records that this was done.

b. *Children 7 to 12 years old:* In most cases, children this age will be able to participate in the assent process using a simplified assent form (adapted from the CPHS template assent forms for 7-12 year olds). The child should sign the form if possible. *If not, the form or study records must still document that verbal assent was obtained.*

A separate, more detailed permission form will be needed for the parents, adapted from the CPHS template parent permission forms.

c. *Adolescents 13 to 17 years old:* In most cases, adolescents should be fully informed about a study and give signed assent to their own participation in the research.

- An assent form should be written for the adolescents, adapted from the CPHS template assent form for 13-17 year olds. Depending on the complexity of the study and the condition/capacity of the adolescent subject, this assent form may be very similar to the parent permission form, or it may need to be somewhat simpler than the adult's form.

- In some cases, e.g. where the parent permission form will be identical in content to the adolescent assent form, the investigator may propose using one form, with signature lines for the adolescent's assent followed by the parent's permission. The form should be adapted from the CPHS template assent form for 13-17 year olds, and address the adolescent subject throughout as “you.”

2. **Waiver of Documented (Signed) Permission**

The CPHS may waive the requirements to obtain documented (signed) parent/guardian permission under the same conditions that apply to waiving signed consent from adult subjects. Per 45 CFR 46.117(c), the CPHS must find either:

1. That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality;

OR

2. That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context.

OR

3. If subjects or legally authorized representative are members of a distinct cultural group or community in which signing forms is not the norm, that the research presents no more than minimal risks of harm to subjects and provided there is an appropriate alternative mechanism for documenting that informed consent was obtained.

The investigator must request this waiver by selecting "Unsigned Parent/Guardian Permission" as the "Type of Permission" in the CPHS application. (As signed assent is not required under the regulations, a formal waiver of signed assent need not be requested. However, the PI should make clear in the application whether or not signed assent will be sought and why.)

*Note:* In cases where the documentation requirement is waived, there must be a mechanism in place to obtain “active permission” from parents (e.g. with a verbal response). “Passive consent” or “opt-out consent” are not recognized consent methods under federal regulations and their use would require a complete waiver of informed consent.
F. Posting Clinical Trial Consent Forms

1. For clinical trials conducted or supported by a Federal department or agency, an IRB-approved informed consent form used to enroll subjects must be posted by the awardee or the Federal department or agency component conducting the trial on a publicly available Federal Web site (e.g. clinicaltrials.gov) that will be established as a repository for such informed consent forms.

2. If the Federal department or agency supporting or conducting the clinical trial determines that certain information should not be made publicly available on a Federal Web site, such Federal department or agency may permit or require redactions to the information posted.

3. The informed consent form must be posted on the Federal Web site after the clinical trial is closed to recruitment and no later than 60 days after the last study visit by any subject, as required by the protocol.